97,741 Shares in Boston Scientific Corporation $BSX Bought by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 97,741 shares of the medical equipment provider’s stock, valued at approximately $4,266,000.

Other large investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new stake in Boston Scientific during the second quarter worth $2,156,233,000. Janus Henderson Group PLC lifted its stake in Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Amundi boosted its holdings in shares of Boston Scientific by 13.8% in the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after purchasing an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after purchasing an additional 2,856,040 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $42.82 on Monday. The company has a market cap of $62.06 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 1.27 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. The firm has a 50 day simple moving average of $44.32 and a 200 day simple moving average of $55.70. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the company posted $0.75 EPS. Boston Scientific’s quarterly revenue was up 1.4% compared to the same quarter last year. Research analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BSX. Wells Fargo & Company decreased their price target on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Royal Bank Of Canada reduced their price objective on Boston Scientific from $70.00 to $52.00 and set an “outperform” rating on the stock in a research note on Thursday, October 29th. Argus lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group decreased their target price on Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.